RxDoctor Payments Data

Mark Desnoyers, MD

Cardiovascular Disease · North Dartmouth, MANPI 1245283167

Payments from drug & device makers

$159in general payments, 2019–2025

Across 10 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$69
  • Boston Scientific$22
  • Merck$22
  • Novo Nordisk$18
  • AstraZeneca$14
  • E.r. Squibb & Sons, L.L.C.$14

What the payments were for

  • Food & beverage$12378%
  • Education$3622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$159 in reported general payments places this provider in the 20th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$368,112
Medicare patients
1,453
Services billed
5,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban819$779,009
EntrestoSacubitril/Valsartan225$200,110
XareltoRivaroxaban121$130,458
JardianceEmpagliflozin90$90,504
Metoprolol Succinate1,606$29,049
JanuviaSitagliptin Phosphate35$28,477
Repatha SureclickEvolocumab17$18,064
FarxigaDapagliflozin Propanediol18$15,783
Atorvastatin Calcium1,386$15,616
TradjentaLinagliptin13$13,345
Repatha SyringeEvolocumab15$12,404
Praluent PenAlirocumab20$11,360
MyrbetriqMirabegron13$11,089
Rosuvastatin Calcium282$8,532
Diltiazem 24hr Er (Cd)Diltiazem Hcl124$6,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$69$130,458121 claims
MerckJanuvia$22$28,47735 claims
AstraZenecaFarxiga$14$15,78318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in North Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →